Christopher Brightling on tezepelumab in patients with moderate-to-severe uncontrolled asthma
Release Date:
Christopher Brightling discusses the effect of blocking thymic stromal lymphopoietin (TSLP) with tezepelumab in patients with moderate-to-severe uncontrolled asthma.Read the full article:https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00226-5/fulltextContinue this conversation on social!Follow us today at...https://twitter.com/thelancethttps://instagram.com/thelancetgrouphttps://facebook.com/thelancetmedicaljournalhttps://linkedIn.com/company/the-lancethttps://youtube.com/thelancettv
Christopher Brightling on tezepelumab in patients with moderate-to-severe uncontrolled asthma